Search
EHA, in partnership with ISTH, award two fellows to support global educational opportunities
EHA and the International Society on Thrombosis and Hemostasis (ISTH) jointly awarded two joint ISTH-EHA Training Fellowships to Araci Rondon (The Netherlands) and Dianne van der Wal (Australia).
Read morePublications
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.
Publications
The publications of the ESLHO networks can be found on the following pages:
EuroFlow publications
EuroMRD publications
EuroClonality publications
The publications from 2023 are also listed below.
Publications
Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance
Schutgens REG, Jimenez-Yuste V, Escobar M, Falanga A, Gigante B, Klamroth R, Lassila R, Leebeek FWG, Makris M, Owaidah T, Sholzberg M, Tiede A, Werring DJ, van der Worp HB,…
Chairs and Members
Chairs
Chair ESLHO: Prof Dr J. J. M. van Dongen, USAL, Salamanca, Spain
Chair EuroFlow: Prof Dr J. J. M van Dongen, USAL, Salamanca, Spain
Chair EuroMRD: Prof Dr M.
Publications
For the subgroup Rare hereditary blood cancers:
GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML.
Exciting developments in Lymphoma (lymphnode cancer) and Myeloma (plasma cell cancer) to be presented at European Hematology Congress in Stockholm, June 13-16, 2013
Myeloma, until recently a fatal bone marrow malignancy with a short survival time, is now turning into a chronic disease.
Read morePress release: 18th Congress of the European Hematology Association in Stockholm, Sweden June 13-16-2013
The EHA-theme of the year, from June 2013 to June 2014, is dedicated to “Age and Aging in blood disorders”.
Read moreHematopoietic stem cells: New results to be presented at the 18th Congress of the EHA
During ageing, this fine-tuned regulatory network may become altered, leading to abnormal HSC regulation. The functional quality of HSCs decreases with age partly due to an accumulation of damaged DNA, leading to an increased incidence of hematological malignancies.
Read morePromising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013
What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.
Read more